Company logo

NuChem Sciences - Sygnature Discovery North America

Medicinal chemistry
Drug discovery
Chemical synthesis
Assay development
Cro

NuChem Sciences - Sygnature Discovery North America information

NuChem Sciences a CRO specialized in integrated services for drug discovery. We Transform Ideas Through Science. With an unparalleled knowledge base and a truly unique collaborative process, NuChem propels the dream of a potential breakthrough into a workable reality by launching the Discovery Partner Program. Since August 2023, NuChem Sciences is now a Sygnature Discovery business.

Employees

Adam Covello
Human Resources Advisor
Arvind Soni
Research Scientist
Benjamin Ovadia
Principal scientist I
Brij Ahuja
Scientist
Corentin Cruche
Scientifique

Looking for a particular NuChem Sciences - Sygnature Discovery North America Employee?

NuChem Sciences - Sygnature Discovery North America's financial review

NuChem Sciences - Sygnature Discovery North America's Revenue (Yearly)

5.6M

Total Funding

29.9M

Employees

200

Last Funding Round

29.9M


Technologies

Alumni

David Claveau
Vice-president, Business Development, North America
Sygnature Discovery
Ivan Franzoni
Senior Scientist
Recursion
Marc Janes
Senior Vice President, Commercial and Strategic Partnerships
Sygnature Discovery

Employees

Adam Covello
Human Resources Advisor
Arvind Soni
Research Scientist
Benjamin Ovadia
Principal scientist I
Brij Ahuja
Scientist
Corentin Cruche
Scientifique

Looking for a particular NuChem Sciences - Sygnature Discovery North America Employee?

NuChem Sciences - Sygnature Discovery North America's financial review

NuChem Sciences - Sygnature Discovery North America's Revenue (Yearly)

5.6M

Total Funding

29.9M

Employees

200

Last Funding Round

29.9M


Prospect on LinkedIn

Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
Represents linkedin prospector

See why over 1,000,000

people joined Apollo last year

Evolve your team’s engagement & intelligence today.